Dermatological manifestations during COVID-19 infection: a case series and discussion on the problem of differential diagnosis.
Keywords:
dermatologic manifestation in covid infection, remdesevir hypersensitivity, covid and urticaria, sacral vasculitis in covid infection, management of urticaria in covid infectionAbstract
On March 11, 2019 the World Health Organization (WHO) declared Coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, as a pandemic. As of 15/01/2021, more than ninety million cases of infections have been confirmed, with almost two million related deaths.
SARS-CoV-2 causes bilateral interstitial pneumonia, which can responsible of respiratory failure in the most severe cases, but the virus has also a wide range of other manifestations, including gastrointestinal, cardiovascular, neurological, and cutaneous signs and symptoms. Cutaneous manifestations are an important matter of study for allergy specialists, as they can be specific signs of the infection, but also manifestations of adverse reactions to the medical therapy in use.
In this case series, we report four different cases of dermatological manifestations in COVID patients, two in hospitalised patients and two in patients with mild disease, treated at home. The first case reported is a woman, who develops urticaria while being treated at home with mild COVID-infection; the second and the third one case reported are drug- hypersensivity reaction to remdesevir and low molecular weight heparin. The last case reported is a man with mild covid with vasculitic sacral lesions.
Key words: COVID pandemic, SARS-CoV-2, dermatological manifestation in covid infections, remdesevir hypersensitivity, covid and urticaria, covid and vasculitic lesions.
References
World Health Organization – WHO Coronavirus Disease Dashboard. covid19.who.int
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239–1242
Hamming I, Timens W, Bulthuis MLC, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203: 631-637
Galván Casas C et al. A large, prospective cohort analysis of patients with cutaneous manifestations and suspected or confirmed COVID-19. Br J Dermatol. 2020;183(1):71–7.
Recalcati S. Letters to the editor: Cutaneous manifestations in COVID-19: a first perspective. JEADV 2020, 34, e210–e240
Mawhirt S L et al. Cutaneous Manifestations in Adult Patients with COVID-19 and Dermatologic Conditions Related to the COVID-19 Pandemic in Health Care Workers. Current Allergy and Asthma Reports (2020) 20:75
Rahimi H, Tehranchinia Z. A comprehensive review of cutaneous manifestations associated with COVID‐19. Biomed Res Int. 2020;2020:1236520.
Galván Casas C, Català A et al. Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020 183:3-4. https://doi.org/10.1111/bjd.19163
Imbalzano E, Casciaro M, Quartuccio S, et al. Association between urticaria and virus infections: a systematic review. Allergy Asthma Proc. 2016;37(1):18‐22. doi: 10.2500/aap.2016.37.3915
Diotallevi F, Campanati A, Bianchelli T, et al. Skin involvement in SARS‐CoV‐2 infection: case series. J Med Virol. 2020;1‐3. https://doi.org/10.1002/jmv.26012
Shanshal M. Low-dose systemic steroids, an emerging therapeutic option for COVID-19 related urticaria J Dermatolog Treat. 2020 Jul 16;1-2. doi: 10.1080/09546634.2020.1795062
Downloads
Published
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
